Analysed WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) News Sources
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
20-05-2026
yahoo.com
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
21-05-2026
yahoo.com
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise
22-05-2026
stocktwits.com
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
28-05-2026
yahoo.com
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
30-05-2026
yahoo.com
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?
10-06-2026
yahoo.com
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
07-07-2026
yahoo.com
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21-07-2026
yahoo.com
What is the current price of WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ)?
The current price of WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) is $3.85.
WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) absolute price change since previous trading day?
The absolute price change of WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) since the previous trading day is $0.
WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) percentage price change since previous trading day?
The percentage price change of WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ)?
The most recent average sentiment score for WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ)?
The most recent sentiment for WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ) is .
SEC-8K** Filing Available For WHITEHAWK THERAPEUTICS INC (WHWK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.